{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Guardant Health, Inc.
Guardant Health Reaches New 52-Week High of $95.88, Up 207%
Guardant Health, Inc. achieved a new 52-week high of USD 95.88 on October 30, 2025, reflecting a remarkable 207.42% increase over the past year. Despite being loss-making, the company has strong financial metrics and a market capitalization of USD 7,503 million, indicating its potential in the Pharmaceuticals & Biotechnology industry.
Guardant Health Hits New 52-Week High of $72.70, Surges 140%
Guardant Health, Inc. has achieved a new 52-week high, reflecting its strong performance in the Pharmaceuticals & Biotechnology sector with a notable one-year gain. The company, classified as small-cap, has impressive financial metrics despite being loss-making and lacking a dividend yield, indicating its strategic positioning in the industry.
Is Guardant Health, Inc. technically bullish or bearish?
As of August 7, 2025, Guardant Health, Inc. shows a bullish trend with strong MACD and KST indicators, despite mixed signals from the monthly RSI and Dow Theory, and has significantly outperformed the S&P 500 with a year-to-date return of 92.47% compared to 12.22%.
Is Guardant Health, Inc. technically bullish or bearish?
As of June 10, 2025, the technical trend is bullish, supported by strong MACD indicators and moving averages, despite some mixed signals from the KST and Dow Theory, with the stock showing a 27.76% return over the past month, outperforming the S&P 500.
Who are in the management team of Guardant Health, Inc.?
As of March 2022, the management team of Guardant Health, Inc. includes AmirAli Talasaz (Chairman, President, COO), Helmy Eltoukhy (CEO, Director), Ian Clark (Lead Independent Director), and several independent directors: Vijaya Gadde, Bahija Jallal, Samir Kaul, and Stanley Meresman. They oversee the company's strategic direction and operations.
What does Guardant Health, Inc. do?
Guardant Health, Inc. is a precision oncology company that develops blood tests and analytics to aid in cancer treatment. As of March 2025, it reported net sales of $203 million and a net loss of $95 million, with a market cap of approximately $6.14 billion.
How big is Guardant Health, Inc.?
As of Jun 18, Guardant Health, Inc. has a market capitalization of $6.14 billion, with net sales of $774 million and a net profit of -$416.55 million over the last four quarters. Shareholder's funds are reported at -$139.65 million, and total assets amount to $1.49 billion.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
